Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Kyle LaHucik

Senior Reporter

Merck, the third-largest pharma R&D spender in 2021, has enlisted outside help in funding its mid-stage schizophrenia program as the Big Pharma looks to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Roy­al­ty Phar­ma bets Mer­ck­'s schiz­o­phre­nia drug can go where Pfiz­er, Take­da and Lund­beck­'s couldn’t

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?